{"id":1775,"date":"2017-01-12T12:02:22","date_gmt":"2017-01-12T12:02:22","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=1775"},"modified":"2021-07-24T12:56:37","modified_gmt":"2021-07-24T07:26:37","slug":"business-cocktail-9","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-9","title":{"rendered":"Aurobindo takes top generic spot; Valeant unloads Dendreon; Ipsen strikes $1B deal; Takeda shells out $5.2B"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69d0f75c17a41\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69d0f75c17a41\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-9\/#Aurobindo_takes_top_generic_spot_in_Portugal_with_E135M_deal_for_Generis_Farmaceutica\" >Aurobindo takes top generic spot in Portugal with \u20ac135M deal for Generis Farmac\u00eautica<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-9\/#Valeant_unloads_Dendreon_and_skin_care_brands_for_21B_in_turnaround_cash\" >Valeant unloads Dendreon and skin care brands for $2.1B in turnaround cash<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-9\/#Frances_Ipsen_strikes_1B_deal_in_big_push_in_US_oncology\" >France&#8217;s Ipsen strikes $1B deal in big push in U.S. oncology<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-9\/#Takeda_shells_out_52B_for_Ariad_Iclusig_and_its_fledgling_med_brigatinib\" >Takeda shells out $5.2B for Ariad, Iclusig and its fledgling med brigatinib<\/a><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Aurobindo_takes_top_generic_spot_in_Portugal_with_E135M_deal_for_Generis_Farmaceutica\"><\/span>Aurobindo takes top generic spot in Portugal with \u20ac135M deal for Generis Farmac\u00eautica<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>India\u2019s Aurobindo Pharma, which has been building its presence around the world, has struck a new deal to buy a generics manufacturer and plant in Portugal which it says will make it the largest generics manufacturer in that country.\u00a0 Aurobindo will pay about \u20ac135 million to buy Generis Farmac\u00eautica and a handful of subsidiaries from Magnum Capital Partners. In addition to producing for the Portuguese market, the Indian drug maker will use the facility to supplement its European production. Generis is projected to have sales of about \u20ac64.8 million for 2016. Aurobindo projects that it can extract about \u20ac2 million in savings from its combined operations in 2018 and \u20ac5 million in 2019.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Valeant_unloads_Dendreon_and_skin_care_brands_for_21B_in_turnaround_cash\"><\/span>Valeant unloads Dendreon and skin care brands for $2.1B in turnaround cash<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Valeant is using the J.P. Morgan Healthcare Conference to make a big statement about its arduous turnaround, which is largely focused on paying down its $30 billion debt burden. The company announced a couple of long-awaited asset sales that will yield $2.1 billion in cash. Valeant plans to unload its equity interest in cancer drug maker Dendreon, which has had a troubled history of its own, as well as its skincare brands CeraVe, AcneFree and AMBI. Valeant agreed to offload those skincare brands to cosmetics giant L&#8217;Or\u00e9al for $1.3 billion in cash. The three products have annualized revenues of $168 million, and demonstrates the \u201cprogress\u201d Valeant is making \u201cin reshaping our product portfolio and driving value for our shareholders.\u201d The company will use the proceeds to repay debt.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Frances_Ipsen_strikes_1B_deal_in_big_push_in_US_oncology\"><\/span>France&#8217;s Ipsen strikes $1B deal in big push in U.S. oncology<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Ipsen has reached an agreement to buy the underperforming pancreatic cancer drug of U.S.-based Merrimack Pharmaceuticals in a deal that could top $1 billion. Ipsen, which has been building its U.S. presence for several years, will pay Merrimack $575 million in cash when the deal closes, which is expected by the end of the quarter, and up to $450 million in additional milestone payments. For that, Ipsen gets the U.S. rights to current and future uses of Onivyde, as well as the licensing agreement with Shire for rights to the drug outside the U.S. It also gets Merrimack\u2019s U.S. manufacturing operations and will take on about 100 employees, mostly in manufacturing, but also a few commercial employees as well as some in R&amp;D. Ipsen will also add Merrimack\u2019s generic version of ovarian cancer drug Doxil.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Takeda_shells_out_52B_for_Ariad_Iclusig_and_its_fledgling_med_brigatinib\"><\/span>Takeda shells out $5.2B for Ariad, Iclusig and its fledgling med brigatinib<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Takeda just snapped up a deal with Ariad Pharmaceuticals, a cancer-focused drug maker with a marketed product to bring in current revenue and a pipeline that offers near-term prospects. In a deal valued at $5.2 billion, Takeda plans to shell out $24 per share for Ariad and its leukemia drug Iclusig and its late-stage ALK-inhibiting lung cancer drug brigatinib, now under priority review at the FDA. With the patent on its blockbuster multiple myeloma med Velcade expiring this year, Takeda reportedly set aside $15 billion last fall to make deals, focusing on cancer, gastrointestinal disorders and neurological diseases. Its new Crohn\u2019s disease drug, Entyvio, has taken off quickly, as has its top seller\u2019s intended successor, Ninlaro, but the company needs more than a couple of products to make up the Velcade difference in the near term. Ariad is an obvious fit with Takeda Oncology, with its expertise in blood cancers and desire to branch out into different forms of the disease.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Aurobindo takes top generic spot in Portugal with \u20ac135M deal for Generis Farmac\u00eautica India\u2019s Aurobindo Pharma, which has been building its presence around the world, has struck a new deal to buy a generics manufacturer and plant in Portugal which it says will make it the largest generics manufacturer in that country.\u00a0 Aurobindo will pay [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1200,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[17419,894,17420],"industry":[17225],"therapeutic_areas":[17228,17278],"class_list":["post-1775","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-aurobindo-pharma","tag-dendreon","tag-ipsen","industry-pharmaceutical","therapeutic_areas-oncology","therapeutic_areas-other-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Aurobindo takes top generic spot; Valeant unloads Dendreon<\/title>\n<meta name=\"description\" content=\"India\u2019s Aurobindo Pharma, which has been building its presence around the world, has struck a new deal to buy a generics manufacturer and plant in...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-9\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aurobindo takes top generic spot; Valeant unloads Dendreon\" \/>\n<meta property=\"og:description\" content=\"India\u2019s Aurobindo Pharma, which has been building its presence around the world, has struck a new deal to buy a generics manufacturer and plant in...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-9\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-01-12T12:02:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/15170357\/14130776__original.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Aurobindo takes top generic spot; Valeant unloads Dendreon","description":"India\u2019s Aurobindo Pharma, which has been building its presence around the world, has struck a new deal to buy a generics manufacturer and plant in...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-9","og_locale":"en_US","og_type":"article","og_title":"Aurobindo takes top generic spot; Valeant unloads Dendreon","og_description":"India\u2019s Aurobindo Pharma, which has been building its presence around the world, has struck a new deal to buy a generics manufacturer and plant in...","og_url":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-9","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2017-01-12T12:02:22+00:00","article_modified_time":"2021-07-24T07:26:37+00:00","og_image":[{"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/15170357\/14130776__original.jpg","width":1,"height":1,"type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-9","url":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-9","name":"Aurobindo takes top generic spot; Valeant unloads Dendreon","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-9#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-9#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/15170357\/14130776__original.jpg","datePublished":"2017-01-12T12:02:22+00:00","dateModified":"2021-07-24T07:26:37+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"India\u2019s Aurobindo Pharma, which has been building its presence around the world, has struck a new deal to buy a generics manufacturer and plant in...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/business-cocktail-9"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-9#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/15170357\/14130776__original.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/15170357\/14130776__original.jpg","caption":"Blue globes from drug capsule"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/15170357\/14130776__original.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Aurobindo Pharma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Dendreon<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ipsen<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Aurobindo Pharma<\/span>","<span class=\"advgb-post-tax-term\">Dendreon<\/span>","<span class=\"advgb-post-tax-term\">Ipsen<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 9 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Jan 12, 2017","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Jan 12, 2017 12:02 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"Blue globes from drug capsule","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1775","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=1775"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1775\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/1200"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=1775"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=1775"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=1775"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=1775"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=1775"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}